GlassScriptPhysician profile
Gabrielle Olivas
NPI 1578108775
$709.62
in general payments reported to CMS, 2019-2025
12 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.46 · 2022: $121 · 2024: $74.51 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.75 | 2025 | |
| Dompe US, INC. | $121.22 | 2022 | |
| Soleno Therapeutics, INC. | $77.48 | 2025 | Vykat Xr |
| Ascendis Pharma Endocrinology INC | $40.25 | 2024 | |
| Tolmar, INC. | $38.30 | 2025 | Fensolvi |
| Insulet Corporation | $34.26 | 2024 | Omnipod |
| Boston Scientific Corporation | $22.19 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.44 | 2025 | Strensiq |
| Merck Sharp & Dohme LLC | $17.49 | 2025 | Gardasil 9 |
| Spark Therapeutics, INC. | $17.27 | 2021 | |
| Pfizer INC. | $16.34 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.63 | 2025 | Triptodur |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Olivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.